Yuxia Yao

Yuxia Yao

Auto-generated profile, based on publicly available information

Yuxia Yao

Department of Digestive Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing 101100, China

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2018 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
QSQiang Su
Qiang Su
XZXiao-Chen Zhang
Xiao-Chen Zhang
CZChen-Guang Zhang
Chen-Guang Zhang
YHYanli Hou
Yanli Hou
YYYu-Xia Yao
Yu-Xia Yao
BCBangwei Cao
Bangwei Cao
We performed a systematic review and meta-analysis to determine the risk of immune-related pancreatitis associated with the treatment by immune checkpoint inhibitors (ICIs) for solid tumors. Eligible studies were selected from multiple databases including phase II/III randomized controlled trials (RCTs) with ICIs in solid tumor patients. The data were analyzed with Stata version 12.0 software. After excluding ineligible studies, a total of 15 clinical trials were considered eligible for the meta-analysis, which included 9099 patients. Compared with chemotherapy or placebo, the risk ratio (RR) for all-grade lipase elevation after CTLA-4 inhibitor treatment was 1.05 (95% confidence interval (CI): 1.01–2.24, p=0.047). However, the risk for pancreatitis after ICI treatment in any subgroup was not significantly higher than that after control therapy. In addition, compared with ipilimumab/nivolumab alone, the RR for all-grade and high-grade lipase elevation under combination treatment of nivolumab and ipilimumab was 6.43 (95% CI: 1.43–28.99, p=0.015) and 6.44 (95% CI: 1.39–29.79, p=0.017), respectively, and the RR for all-grade amylase elevation under combination treatment was 6.08 (95% CI: 1.51–24.44, p=0.011). Our meta-analysis has demonstrated that both CTLA-4 inhibitors alone and combination treatment of nivolumab and ipilimumab could increase the risk of amylase or lipase elevation, but not significantly increase the risk of pancreatitis when compared with controls.

4 November 2018 in BioMed Research International
Verified
Journal Article
Open access
PDF file
YYYu-Xia Yao
Yu-Xia Yao
BXBao-Hong Xu
Bao-Hong Xu
YZYan Zhang
Yan Zhang
Aim. Colon cancer-associated transcript-1 (CCAT1), located in the vicinity of transcription factor c-Myc, was first identified in colon cancer. A small-molecule compound CX3543 (Quarfloxin) selectively targeting Myc G-quadruplexes has entered phase II clinical trials for neuroendocrine carcinomas. The aim of the study was to explore the relationship between CX3543, CCAT1, and cell apoptosis in colon cancer cells. Methods. Semiquantitative PCR was used to detect the relative expression of CCAT1 in colon cancer (CC) tissues and HT29 cell lines. Real-time PCR (RT-PCR) was also used to investigate the expression of CCAT1 and c-Myc after HT29 cells being treated by CX3543 for 24 h. Cell apoptosis assay and cell proliferation assay were conducted in HT29 cells after being treated by CX3543. Results. The results showed that the expression of CCAT1 was remarkably increased in CC tissues and HT29 cells compared to controls. CX3543 treatment reduced the expression of c-Myc and CCAT1 and promoted cell apoptosis and inhibited cell proliferation. After the expression of CCAT1 was inhibited by sh-CCAT1 transfection, the cell apoptosis rate was higher than that of control group. After the cells were treated by CCAT1 overexpression plasmid transfection and CX3543, the cell apoptosis rate was lower than that of control group. In vivo results showed that CX3543 inhibited the xenograft tumor growth of rats through downregulation of CCAT1. Conclusion. Our study demonstrated that CX3543 could inhibit the progression of colon cancer by downregulating CCAT1 expression and might be a potential drug for the treatment of colon cancer.

1 May 2009
Verified
Conference Paper
Closed access
MIMudasser Iqbal
Mudasser Iqbal
HLHock Beng Lim
Hock Beng Lim
WWWenqiang Wang
Wenqiang Wang
YYYuxia Yao
Yuxia Yao
The emerging heterogeneity of data management, programming models and operating platforms in sensor nodes are making the seamless interoperation of devices a challenge. We consider this problem and leverage on the concepts of semantic web and service-oriented design to propose a model that adds a semantics and service-oriented layer to existing network models. This added layer hides the hardware as well as software implementation details from the application layer and thus allows seamless data management between nodes whose capabilities may even be unknown. The proposed model builds on top of well established standards OWL and OWL-S to encapsulate sensor data and services as hierarchical ontology and provides interfaces for service advertisement and discovery. A case study has been discussed whereby the proposed model is used for service-oriented data management (acquisition, archival, processing).

6 November 2007
Verified
Conference Paper
Open access
PDF file
HLHock Beng Lim
Hock Beng Lim
KLKeck Voon Ling
Keck Voon Ling
WWWenqiang Wang
Wenqiang Wang
YYYuxia Yao
Yuxia Yao
MIMudasser Iqbal
Mudasser Iqbal
TSTarun Sharma
Tarun Sharma